PreludeDx continues to drive innovation in early breast cancer and is dedicated to developing the highest quality clinical evidence.
As part of this initiative, PreludeDx is conducting a large prospective decision impact registry study called DCISionRT PREDICT, or Prospective Registry study to Evaluate the effect of the DCISionRT test on treatment Decisions In patients with DCIS following breast Conserving Therapy.
The study will evaluate the impact of DCISionRT, the prognostic and predictive DCIS test, on clinical management of patients with surgically treated DCIS as compared to traditional clinical and pathologic risk factors. The study will enroll 2,500 patients and up to 100 academic and community cancer centers around the US.
ClinicalTrials.gov Identifier: NCT03448926